leisure time -WSS

leisure time

author：hotspot 2025-08-29 19:54:01 - browse：3

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

WSS

Ozempic has benefits for kidney disease as well as diabetes

A new approach to psychiatric drug development

Head of FDA's diagnostics center, who led through Covid, retires

He's 19 months old and has one of the world’s rarest diseases

Stem cell biologist probes earliest stages of human development

Inaction leaves children at risk from dangerous chemotherapy drug

leisure time

leisure time

knowledge

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Medicare details structure of new drug price negotiation program

Fetal cell organoids grown from amniotic fluid, study finds

Activists slam private health insurers over coverage restrictions

HPV vaccine, cervical cancer study delivers historic results

Duchenne breakthrough therapy leaves behind pioneering families

State of the Union pitch: Bigger Medicare drug price negotiations

Medical leaders decry Supreme Court decision on affirmative action

Medicare bonuses could stop drug shortages under Senate plan

focus

Mass General, Mayo Clinic look to monetize custom

The untold story of TV’s first prescription drug ad

Mass General, Mayo Clinic look to monetize custom

Medicare bonuses could stop drug shortages under Senate plan

The inclusion problem at the heart of rehabilitation research

Head of FDA's diagnostics center, who led through Covid, retires

explore

hotspot

Wikipedia

leisure time